Number of shares and votes in BioArctic AB (publ) as of November 30, 2022
Stockholm, November 30, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during November issued 71, 586 B shares for delivery ...
Press releases
Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s disease published in the New England Journal of Medicine
Stockholm, November 30, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory ...
BioArctic’s partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer’s disease at CTAD conference
Stockholm, November 30, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory ...
Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference
Stockholm, November 21, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the efficacy, safety and biomarker results from the Phase 3 ...
BioArctic expands portfolio with alpha-synuclein Brain Transporter project
Stockholm, November 17, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company is expanding its alpha-synuclein project portfolio. The new project, ...
BioArctic receives new patent in the US for blood-brain barrier transport technology
Stockholm, November 14, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted BioArctic a ...
BioArctic develops new treatment for Gaucher’s disease
Stockholm, November 8, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has initiated a new project focused on enzyme replacement ...
BioArctic’s founders intend to divest minor part of their shareholding
Stockholm, October 25, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been made aware that the company’s two founders and main shareholders, Lars Lannfelt ...
Interim Report for the period July – September 2022
Groundbreaking results for lecanemab in Phase 3 study in early Alzheimer's disease Events during the third quarter 2022 Lecanemab showed positive results in the pivotal Phase ...
BioArctic presents Nomination Committee
Stockholm, Sweden, October 18, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 5, 2022, adopted an instruction regarding the appointment ...
Invitation to presentation of BioArctic’s third quarter report for July – September 2022 on October 20 at 9.30 a.m. CET
Stockholm, Sweden, October 14, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report for July – September 2022 on Thursday, ...
Lecanemab phase 3 Clarity AD study in early Alzheimer’s disease meets primary and all key secondary endpoints with high statistical significance
Stockholm, September 28, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced positive topline results for the large global Phase 3 confirmatory ...
Latest data on lecanemab presented at Alzheimer’s Association International Conference (AAIC)
Stockholm, August 5, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril ...
Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC)
Stockholm, July 26, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) ...
Interim Report for the period April – June 2022
FDA grants priority review for lecanemab marketing application Events during the second quarter 2022 Eisai completed the rolling submission of lecanemab for treatment of early Alzheimer’s ...
The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alzheimer’s disease under the accelerated approval pathway
Stockholm, July 6, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration (FDA) has accepted ...
Invitation to presentation of BioArctic’s second quarter report for April – June 2022 on July 12 at 9.30 a.m. CET
Stockholm, Sweden, July 5, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s second quarter report for April – June 2022 on Tuesday, July ...
Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer’s disease under the accelerated approval pathway
Stockholm, May 10, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have completed the rolling submission to the U.S. ...
BioArctic receives new drug substance patent in the US for ABBV-0805 against Parkinson’s disease
Stockholm, May 6, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted a new ...
Report from annual general meeting in BioArctic AB (publ)
Stockholm, Sweden, May 5, 2022 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. Due to Covid-19, the Annual General Meeting ...
Interim Report for the period January – March 2022
Decision on marketing approval for lecanemab is approaching Events during the first quarter 2022 Eisai commenced submission of lecanemab data in Japan for a prior ...
Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer’s dementia by several years
Stockholm, April 27, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that an article about long-term health outcomes of the investigational ...
Invitation to presentation of BioArctic’s First Quarter Report for January – March 2022 on April 28 at 9.30 a.m. CET
Stockholm, Sweden, April 20, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s First Quarter Report for January – March 2022 on ...
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
Stockholm, April 20, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has announced that the company’s partner AbbVie has decided to terminate its collaboration with ...
Notice of Annual General Meeting in BioArctic AB (Publ)
The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, 5 May 2022
BioArctic publishes the Annual Report for 2021
Stockholm March 31, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2021 Annual Report has been published. ...
BioArctic and Eisai presented latest data regarding lecanemab at the AD/PD[TM] 2022 conference
Stockholm, March 21, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401) – an investigational anti-amyloid-beta ...
Latest lecanemab data to be presented at the AD/PD™ congress
Stockholm, March 11, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data ...
The Nomination Committee’s proposal for the election of board members in BioArctic AB
Stockholm March 9, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals ...
Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval
Stockholm, March 4, 2022 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) ...
BioArctic continues to build its commercial organization
Stockholm, February 18, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) continues to build the Nordic commercial organization ahead of a potential launch of the ...
Interim Report for the period October – December 2021
A time of hope for Alzheimer’s patients
Invitation to presentation of BioArctic’s Full Year Report for January – December 2021 on February 3 at 9.30 a.m. CET
Stockholm, Sweden, January 27, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Full Year Report for January – December 2021 on Thursday, February ...
DIAN-TU enrolls first subject for the Tau NexGen study with lecanemab as back-ground anti-amyloid treatment
Stockholm, January 19, 2022 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led ...
Lecanemab granted Fast Track designation by the FDA
Stockholm, December 24, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for ...
BioArctic develops new antibody treatment for ALS
Stockholm, November 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today gave an update on the company’s development project ND3014. For the first time, ...
New data on lecanemab presented at the CTAD Alzheimer conference
Stockholm, November 15, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai held several oral presentations at the 14[th] Clinical Trials on Alzheimer’s ...
DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer’s disease
Stockholm, November 8, 2021 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led ...
New data published on ABBV-0805 in Neurobiology of Disease
Stockholm, November 8, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has published an article in Neurobiology of Disease describing new preclinical data for the ...
New data on lecanemab to be presented at the 14[th] Clinical Trials on Alzheimer’s Disease (CTAD) conference
Stockholm, November 4, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai today announced that they will hold several oral presentations revealing new ...
BioArctic presents Nomination Committee
Stockholm, Sweden, November 1, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 6, 2021, adopted an instruction regarding the appointment ...
Interim Report for the period July – September 2021
Eisai initiates Biologics License Application of lecanemab in the US earlier than expected Events during the third quarter 2021 Eisai has initiated a rolling submission for ...
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2021 on October 21 at 9.30 a.m. CET
Stockholm, Sweden, October 11, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Interim Report for the period January – September 2021 ...
Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway
Stockholm, September 28, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that they have initiated a rolling submission to the U.S. ...
New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease
Stockholm, September 10, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present new preclinical data for the investigational anti-?-synuclein antibody ABBV-0805 at the International ...
Eisai presented latest data from the lecanemab clinical program at AAIC 2021
Stockholm, July 30, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai held several presentations at the Alzheimer’s Association International Conference (AAIC) in Denver, ...
Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC)
Stockholm, July 21, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer’s Association International Conference (AAIC) to ...
Interim Report for the period April – June 2021
FDA grants Breakthrough Therapy designation for lecanemab Events during the second quarter 2021 The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for lecanemab ...
FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer’s disease
Stockholm, 23 June 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has granted ...
BioArctic receives patent in Japan for new antibodies targeting Alzheimer’s disease
Stockholm, May 11, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) has allowed the company’s ...
Report from annual general meeting in BioArctic AB (publ)
Stockholm, Sweden, May 6, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. Due to the continued spread of the ...
Interim Report for the period January – March 2021
New data continues to strengthen lecanemab
Lecanemab (BAN2401) Phase 2b study in early Alzheimer’s disease published in peer-reviewed journal, Alzheimer’s Research & Therapy
Stockholm April 20, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b ...
Invitation to presentation of BioArctic’s Interim Report for the period January – March 2021 on April 21 at 9.30 a.m. CET
Stockholm, Sweden, April 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)
will publish the company’s Interim Report for the period January – March 2021 ...
Notice of Annual General Meeting in BioArctic AB (publ)
The shareholders in BioArctic AB (publ), corporate identity number 556601-2679 (the “Company” or “BioArctic”) are hereby summoned to the Annual General Meeting to be held on ...
BioArctic publishes the Annual Report for 2020
Stockholm March 31, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2020 Annual Report has been published.
BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021
Stockholm, March 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced data on the drug candidate lecanemab (BAN2401), which were presented by the ...
Latest lecanemab data to be presented at the AD/PD™ congress
Stockholm, March 5, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data ...
The Nomination Committee’s proposal for the election of board members in BioArctic AB
Stockholm February 12, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals ...
Interim Report for the period January – December 2020
New data provides further support for BAN2401 (lecanemab)
Eisai increases the number of participants in Clarity AD study
Stockholm, February 3, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately ...
BioArctic receives European patent for new antibodies targeting Alzheimer’s disease
Stockholm, January 27, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant ...
Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2020 on February 4 at 9.30 a.m. CET
Stockholm, Sweden, January 26, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s Full Year Report for the period January – December ...
Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020
Stockholm, November 9, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the ...
BioArctic’s partner Eisai to present latest data on BAN2401 at CTAD conference
Stockholm, October 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will conduct four oral presentations related to ...
BioArctic winner of the Allbright Award 2020
Stockholm, October 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its ...
Interim Report for the period January – September 2020
An additional Phase 3 study in Alzheimer’s disease
BioArctic presents Nomination Committee
BioArctic presents Nomination Committee Stockholm, Sweden, October 13, 2020 – BioArctic's Annual General Meeting on May 7, 2020, adopted an instruction regarding the appointment of the Nomination ...
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2020 on October 14 at 9.30 a.m. CET
Stockholm, Sweden, October 6, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2020 on Wednesday, ...
Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020
Stockholm, July 30, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai presented the latest data from the open-label ...
BioArctic’s partner Eisai to present update on the development of BAN2401 at Alzheimer’s Association International Conference 2020
Stockholm, July 22, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will present the study design of the ...
New global Phase 3 program of BAN2401 initiated in preclinical (asymptomatic) Alzheimer’s disease
Stockholm, July 14, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its business partner Eisai, in collaboration with Alzheimer’s Clinical Trials Consortium ...
Interim Report for the period January – June 2020
Continued performance according to plan Key events during the second quarter 2020 BioArctic communicated that the mechanism of action for the AD1801 antibody project is ...
Invitation to presentation of BioArctic’s Interim Report for the period January – June 2020 on July 10 at 9.30 a.m. CET
Stockholm, Sweden, July 1, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June ...
BioArctic and University of Oslo sign research agreement to investigate Apolipoprotein E as a drug target for Alzheimer’s disease
Stockholm, Sweden, June 29, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and University of Oslo, Institute of Clinical Medicine (IKM), announced today that they ...
Members of BioArctic’s Board of Directors and management increase their shareholdings
Stockholm, Sweden, May 26, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that seven members of the company's Board and management today have ...
Report from Annual General Meeting in BioArctic (publ)
Stockholm, Sweden, May 7, 2020 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. The following resolutions were adopted. Adoption ...
Interim Report for the period January – March 2020
Operations performing according to plan Key events during the first quarter 2020 As of today, BioArctic has not experienced any noteworthy disruptions to its operations ...
Invitation to presentation of BioArctic’s Interim Report for the first quarter 2020 on April 22 at 9.30 a.m. CET
Stockholm, Sweden, April 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2020 ...
Notice of Annual General Meeting in BioArctic AB (Publ)
The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, 7 May 2020 More information about ...
BioArctic publishes the Annual Report for 2019
Stockholm April 2, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for the 2019 has been published in ...
The Nomination Committee’s proposal for the election of board members in BioArctic AB
Stockholm March 24, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Nomination Committee for BioArctic AB provides the following proposals for ...
Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401
Stockholm, March 3, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will include Swedish clinics in the ...
Full Year Report for the period January – December 2019
Enhanced project portfolio from a successful year
Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2019 on February 6 at 9.30 a.m. CET
Stockholm, Sweden, January 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December ...
BioArctic announces research collaboration with Eisai regarding BAN2401
Stockholm, Sweden, December 17, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the initiation of a research collaboration with Eisai aimed at ...
BioArctic strengthens its management team with two strategic recruitments
Stockholm, Sweden, December 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will be strengthening its management team in 2020 through two strategic recruitments. ...
BioArctic’s partner Eisai presents data from the ongoing BAN2401 Phase 2b extension study in early Alzheimer’s disease
Stockholm, Sweden, December 5, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that data from the ongoing BAN2401 Phase 2b open-label extension study ...
BioArctic and Eisai to present data on BAN2401 at the Clinical Trials on Alzheimer’s Disease conference
Stockholm, Sweden, December 2, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the 12th ...
BioArctic announces results from interim analysis of the Phase 1/2 study of SC0806 in patients with complete spinal cord injury
Stockholm, Sweden, November 18, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the results of an interim analysis of a Phase 1/2 study ...
BioArctic presents Nomination Committee and publishes financial calendar 2020
Stockholm, Sweden, November 5, 2019 – The Annual General Meeting of BioArctic AB on May 9, 2019, adopted instructions regarding the appointment of the Nomination Committee. ...
Interim Report January – September 2019
BioArctic: Strong continued progress year to date Summary of key events for the third quarter 2019 BioArctic and Eisai presented new data regarding BAN2401 at ...
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2019 on October 24 at 9.30 a.m. CET
Stockholm, Sweden, October 16, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September ...
BioArctic and Eisai present new data regarding BAN2401 at the Alzheimer’s Association International Conference 2019
Stockholm, Sweden, July 18, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The ...
BioArctic’s co-founder received AAIC Lifetime Achievement Award
Professor Lars Lannfelt received prestigious international award for outstanding research in Alzheimer’s disease
Interim Report January – June 2019
BioArctic: Significant progress in the projects and additional milestone payment
BioArctic and Eisai to present BAN2401 at the Alzheimer’s Association International Conference 2019
Stockholm, Sweden, July 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at ...
Invitation to presentation of BioArctic’s Interim Report for the second quarter of 2019 on July 11 at 9.30 a.m. CET
Stockholm, Sweden, July 2, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2019 ...
BioArctic strengthens its blood-brain barrier technology platform with world leading scientist recruitment
Stockholm, Sweden, May 23, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited the internationally renowned scientist Dr. ...
BioArctic receives MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s Disease
Stockholm, Sweden, May 20, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR ...
BioArctic: Alzheimer’s Clinical Trials Consortium and Eisai announce BAN2401 to be evaluated in clinical study for prevention of Alzheimer’s disease
Stockholm, Sweden, May 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer’s Clinical Trials Consortium (ACTC) and BioArctic’s partner ...
BioArctic’s Board of Directors and management increase their shareholdings
Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that nine members of the company's Board and management today have called ...
BioArctic – report from the Annual General Meeting 2019
Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting 2019. The following resolutions were adopted:
Interim Report January – March 2019
BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease. Phase 1-study with ABBV-0805 in the Parkinson program started
Invitation to presentation of BioArctic’s Interim Report for the first quarter of 2019 on May 9, at 9.30 a.m. CET
Stockholm, Sweden, April 29, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2019 ...
BioArctic publishes the Annual Report for 2018
Stockholm, Sweden, April 16, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2018 fiscal year has been ...
Notice of Annual General Meeting in BioArctic AB (publ)
The shareholders in BioArctic AB (publ), corporate identity number 556601-2679 (”the Company”) are hereby summoned to the Annual General Meeting to be held on May 9, ...
BioArctic receives grant from Vinnova for a collaborative research project to increase brain uptake of antibodies
Stockholm, Sweden, April 3, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a non-diluting grant of MSEK 5 ...
BioArctic’s partner Eisai to give poster presentations on BAN2401 in early Alzheimer’s disease at the AD/PD conference in Lisbon
Stockholm, Sweden, March 25, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that its partner Eisai will give poster presentations related to BAN2401 in ...
BioArctic’s partner Eisai initiates the confirmatory Phase 3 study of BAN2401 in early Alzheimer’s Disease
Stockholm, Sweden, March 22, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory ...
BioArctic – Statement regarding today’s trading halt
Stockholm, Sweden, March 21, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) comments on the decision today by Nasdaq Stockholm to halt trading in BioArctic ...
BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease
Stockholm, Sweden, March 13, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the ...
BioArctic: Eisai announces timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer’s disease
Stockholm, Sweden, March 7, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informs that Eisai today announced the timelines for the single confirmatory Phase 3 ...
Full Year Report January – December 2018
BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolio
BioArctic’s product candidate SC0806 for treatment of patients with complete spinal cord injury is now in Phase 2
Stockholm, Sweden, February 13, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase ...
BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Application for ABBV-0805
ABBV-0805 is being evaluated as a potential disease modifying treatment for Parkinson’s Disease Stockholm, Sweden, February 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA ...
Invitation to presentation of BioArctic’s Full Year Report 2018 on February 14, 2019
Stockholm, Sweden, February 7, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December ...
BioArctic announces that Eisai will initiate Phase 3 confirmatory study with BAN2401 in early Alzheimer’s Disease
Stockholm, Sweden, February 4, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai stated at their Q3 FY2018 Financial Results Meeting on ...
BioArctic employs Gunilla Andersson as Senior Director HR
Stockholm, Sweden, December 19, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Gunilla Andersson assumes the new position as Senior Director HR ...
BioArctic outlicenses its alpha-synuclein antibody portfolio for Parkinson’s Disease to AbbVie after receiving clearance
Stockholm, Sweden, December 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. ...
BioArctic to present at Jefferies 2018 London Healthcare Conference on November 15
Stockholm, Sweden, November 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present at Jefferies 2018 London Healthcare Conference on November 15, at 4.40 ...
BioArctic is awarded grant from EU’s Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson’s
Stockholm, Sweden, November 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been awarded a grant from EU’s research and innovation program Horizon 2020. ...
Interim Report January – September 2018
BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projects
BioArctic presents Nomination Committee and publishes financial calendar 2019
Stockholm, Sweden, November 6, 2018 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 15, 2018 the members of ...
BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein antibody portfolio for Parkinson’s Disease
Stockholm, Sweden, November 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option Exercise ...
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – September 2018 on Thursday, November 8, 2018 at ...
BioArctic announces additional BAN2401 Phase 2b study results in early Alzheimer’s disease presented by Eisai at the 2018 CTAD conference
Stockholm, Sweden, October 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) previously announced on July 6, 2018 the positive topline results from the clinical ...
BioArctic is granted a concept patent in Europe for the company’s strategy for disease-modifying treatment of Parkinson’s disease
Stockholm, Sweden, October 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to ...
BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD
Stockholm, Sweden, October 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai will present additional data on the anti-amyloid (Aβ) ...
BioArctic receives European patent protection for a medical device for treatment of patients with Complete Spinal Cord Injury
Stockholm, Sweden, October 3, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to ...
BioArctic signs a research agreement with Brain Biomarker Solutions in Gothenburg AB to develop new diagnostics for Alzheimer’s disease
Stockholm, Sweden, September 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has signed a research agreement with Brain Biomarker Solutions in Gothenburg AB (BBS). ...
BioArctic expands the research collaboration with Uppsala University concerning antibody-based diagnostic imaging of the brain in Alzheimer patients
Stockholm, Sweden, September 3, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that the company has signed an expanded research collaboration agreement with ...
Interim Report January – June 2018
Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease April – June 2018 Net revenues for the period amounted to SEK 52.3 ...
Invitation to presentation of BioArctic’s Interim Report for the period January – June 2018 on August 23, 2018
Stockholm, Sweden, August 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2018 ...
BioArctic obtains exclusive rights to develop antibody treatments for Alzheimer’s disease from a research project jointly owned with Eisai
Stockholm, Sweden, August 7, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has in collaboration with Eisai identified a completely new biological target, which provides ...
BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer’s disease presented at AAIC 2018
Stockholm, Sweden, July 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced on July 6 the positive topline results from the clinical Phase ...
BioArctic: Late breaking Phase 2b study results of BAN2401 in Alzheimer’s disease will be webcast live from AAIC 2018 by Eisai
Stockholm, Sweden, July 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B). As previously announced, the BAN2401 Phase 2b clinical study results will be presented ...
BioArctic receives regulatory approval in Finland for a clinical study in patients with Complete Spinal Cord Injury
Stockholm, Sweden, July 10, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by Fimea, the Finnish Medicines ...
BioArctic Announces Acceptance of BAN2401 Phase 2b Results for Oral Presentation at the AAIC 2018
Stockholm, Sweden, July 10, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces today the results of the BAN2401 Phase 2b clinical study (ClinicalTrials.gov identifier ...
BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer’s Disease
The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in early Alzheimer’s disease demonstrated statistically significant and dose-dependent slowing in ...
BioArctic announces changes in the Management Team effective September 1, 2018
Stockholm, Sweden, June 27, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that professor Lars Lannfelt resumes his employment in the company as ...
BioArctic receives this year’s SwedenBIO Award
Stockholm, Sweden, May 16, 2018 – BioArctic AB today received the SwedenBIO Award 2018. The prize is awarded to a company that has distinguished itself by ...
Report from the Annual General Meeting in BioArctic AB (publ)
BioArctic AB (publ) held its Annual General Meeting on Tuesday May 15, 2018. The following resolutions were adopted:
BioArctic extends the research collaboration with Uppsala University regarding new antibody technology
Stockholm, Sweden, May 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has signed an extended research collaboration agreement with ...
Interim Report January – March 2018
Continued progress of the project portfolio January - March 2018 Net sales for the period amounted to SEK 52.3 million (26.2) Operating profit amounted to SEK ...
Inclusion completed of patients with complete spinal cord injury in the first panel of BioArctic’s ongoing study
Stockholm, Sweden, April 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the inclusion of patients with complete spinal cord injury in ...
BioArctic publishes the Annual Report for 2017
Stockholm, Sweden, April 24, 2018 – BioArctic AB (publ.) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2017 fiscal year has ...
NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)
The shareholders in BioArctic AB (publ), corporate identity number 556601-2679, (”the Company”) are hereby summoned to the Annual General Meeting to be held on Tuesday, ...
Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018
Stockholm, Sweden, April 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2018 ...
BioArctic receives regulatory approval in Norway for a clinical study in patients with Complete Spinal Cord Injury
Stockholm, Sweden, March 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Norwegian Medicines Agency ...
BioArctic receives patent protection in Japan for a medical device for treatment of patients with Complete Spinal Cord Injury
Stockholm, Sweden, March 19, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) issued a notification to grant ...
BioArctic receives regulatory approval in Estonia for a clinical study in patients with Complete Spinal Cord Injury
Stockholm, Sweden, February 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Estonian State Agency ...
Full Year Report January – December 2017
Successful IPO and continued positive result for BioArctic. October – December 2017. Net sales for the period amounted to SEK 51.0 million (94.4). Operating profit amounted ...
Invitation to presentation of BioArctic’s Full Year Report 2017 on February 20, 2018
Stockholm, Sweden, February 5, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report 2017 for the period January – ...
BioArctic receives US patent protection for a method with a medical device for treatment of patients with Complete Spinal Cord Injury
Stockholm, Sweden, February 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) published an Issue ...
BioArctic announces that the Phase 2b study of BAN2401 in early Alzheimer´s Disease continues toward 18 month endpoint
Criteria for success at 12 month interim analysis of ADCOMS not met Study to remain blinded per protocol until final readout of comprehensive 18 month data
BioArctic presents Nomination Committee and publishes financial calendar 2018
Stockholm, Sweden, November 9, 2017 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 31, 2017 the members of ...
Interim Report January – September 2017
BioArctic listed on Nasdaq Stockholm Mid Cap. July - September 2017- Net sales for the period amounted to SEK 31.5 million (1.2). Operating profit amounted to SEK ...
EXERCISE OF OVER-ALLOTMENT OPTION AND END OF THE STABILIZATION PERIOD
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
Invitation to presentation of BioArctic’s Interim Report January – September 2017 on November 8
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) publishes the company’s Interim Report for the period January – September 2017 on November 8, 2017 at 08:00 a.m. ...
Change in the number of shares and votes in BioArctic AB (publ)
Stockholm, Sweden, October 31, 2017 – BioArctic AB (publ) (“BioArctic” or the “Company” ) today announced that the number of shares and votes in BioArctic has ...
Stabilization notice
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
BioArctic’s patent for its product candidate antibody BAN0805, for Parkinson’s disease, is now granted in Europe
Stockholm, Sweden, October 13, 2017 – BioArctic AB (publ) (Nasdaq Stockholm:BIOA B) today announced that the European Patent Office (EPO) has decided to grant a European ...
Trading in BioArctic’s B-shares commences today on Nasdaq Stockholm
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
BioArctic AB publishes prospectus for initial public offering on Nasdaq Stockholm
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
BioArctic AB intends to list on Nasdaq Stockholm
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...
BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research
BioArctic announced that it entered into a strategically important collaboration with AbbVie (NYSE: ABBV), a global biopharmaceutical company, to develop and commercialize BioArctic’s portfolio of antibodies ...
Pharmaceutical study starts in Sweden with BAN2401 in early Alzheimer patients
BioArctic Neuroscience AB today announced that the first patient in Sweden has been treated with BAN2401 in a clinical study aimed at patients with an early ...
BioArctic Neuroscience and Elos Medtech start collaboration on new treatment for spinal cord injuries
The Swedish biotech company BioArctic Neuroscience and the medtech company Elos Medtech have today signed a cooperation agreement for a new treatment of spinal cord injuries.
Drug Candidate Receives Orphan Drug Designation
The text below is a translation of a Swedish press release. BioArctic Neuroscience develops treatments to help victims of spinal cord injury. The European Medicines Agency ...
BioArctic Neuroscience and Swenora Biotech Enter Into Exclusive Licensing Agreement
Today the Swedish biotech companies BioArctic Neuroscience and Swenora Biotech have entered into an exclusive licensing agreement for a novel treatment of Spinal Cord Injury Treatment. ...
